Group One Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $683K | Sell |
2,270
-3,275
| -59% | -$988K | ﹤0.01% | 3218 |
|
|
2026
Q1 | $1.83M | Buy |
+5,545
| New | +$1.89M | ﹤0.01% | 2148 |
|
|
2025
Q3 | – | Sell |
-1,134
| Closed | -$462K | – | 8326 |
|
|
2025
Q2 | $370K | Sell |
1,134
-5,068
| -82% | -$1.4M | ﹤0.01% | 3727 |
|
|
2025
Q1 | $1.67M | Buy |
+6,202
| New | +$1.59M | ﹤0.01% | 1990 |
|
|
2022
Q4 | – | Sell |
-1,999
| Closed | -$426K | – | 7158 |
|
|
2022
Q3 | $400K | Sell |
1,999
-60,219
| -97% | -$11.5M | ﹤0.01% | 3454 |
|
|
2022
Q2 | $9.07M | Buy |
62,218
+38,222
| +159% | +$5.42M | 0.01% | 907 |
|
|
2022
Q1 | $3.92M | Buy |
23,996
+2,854
| +13% | +$435K | ﹤0.01% | 1740 |
|
|
2021
Q4 | $3.58M | Buy |
21,142
+9,356
| +79% | +$1.74M | ﹤0.01% | 2007 |
|
|
2021
Q3 | $2.23M | Sell |
11,786
-796
| -6% | -$149K | ﹤0.01% | 2538 |
|
|
2021
Q2 | $2.13M | Sell |
12,582
-25,416
| -67% | -$3.72M | ﹤0.01% | 2577 |
|
|
2021
Q1 | $5.37M | Buy |
+37,998
| New | +$5.72M | 0.01% | 1457 |
|
|
2020
Q3 | – | Sell |
-10,700
| Closed | -$1.52M | – | 6031 |
|
|
2020
Q2 | $1.58M | Buy |
+10,700
| New | +$1.44M | 0.01% | 1636 |
|
|
2019
Q1 | – | Sell |
-1,990
| Closed | -$166K | – | 4743 |
|
|
2018
Q4 | $145K | Sell |
1,990
-27,794
| -93% | -$2.14M | ﹤0.01% | 2922 |
|
|
2018
Q3 | $2.61M | Buy |
29,784
+15,921
| +115% | +$1.6M | 0.02% | 969 |
|
|
2018
Q2 | $1.36M | Buy |
+13,863
| New | +$1.38M | 0.01% | 1417 |
|
|
2018
Q1 | – | Sell |
-8,587
| Closed | -$1.11M | – | 4787 |
|
|
2017
Q4 | $1.09M | Sell |
8,587
-60,156
| -88% | -$7.56M | 0.01% | 1630 |
|
|
2017
Q3 | $8.08M | Buy |
68,743
+41,601
| +153% | +$3.55M | 0.07% | 327 |
|
|
2017
Q2 | $2.17M | Sell |
27,142
-9,747
| -26% | -$623K | 0.02% | 910 |
|
|
2017
Q1 | $1.89M | Buy |
36,889
+14,358
| +64% | +$664K | 0.02% | 901 |
|
|
2016
Q4 | $844K | Buy |
22,531
+11,165
| +98% | +$467K | 0.01% | 1428 |
|
|
2016
Q3 | $770K | Buy |
+11,366
| New | +$802K | 0.01% | 1467 |
|
|
2016
Q1 | – | Sell |
-275
| Closed | -$18.3K | – | 4524 |
|
|
2015
Q4 | $26K | Sell |
275
-15,700
| -98% | -$1.46M | ﹤0.01% | 3772 |
|
|
2015
Q3 | $1.28M | Buy |
15,975
+8,257
| +107% | +$917K | 0.02% | 1066 |
|
|
2015
Q2 | $925K | Buy |
7,718
+4,837
| +168% | +$578K | 0.01% | 1273 |
|
|
2015
Q1 | $301K | Buy |
+2,881
| New | +$292K | ﹤0.01% | 2029 |
|
|
2014
Q4 | – | Sell |
-13,743
| Closed | -$1.27M | – | 4854 |
|
|
2014
Q3 | $1.07M | Buy |
13,743
+6,178
| +82% | +$399K | 0.02% | 1068 |
|
|
2014
Q2 | $478K | Sell |
7,565
-1,642
| -18% | -$97.6K | 0.01% | 1678 |
|
|
2014
Q1 | $618K | Buy |
9,207
+8,772
| +2,017% | +$679K | 0.01% | 1475 |
|
|
2013
Q4 | $28K | Buy |
+435
| New | +$25.9K | ﹤0.01% | 4042 |
|
|
2013
Q3 | – | Sell |
-3,274
| Closed | -$163K | – | 5137 |
|
|
2013
Q2 | $102K | Buy |
+3,274
| New | +$87.1K | ﹤0.01% | 2799 |
|
Other funds holding ALNY
Group One Trading's ALNY Position: Q2 2026 in Review
Group One Trading reduced its Alnylam Pharmaceuticals (ALNY) stake by 59% in Q2 2026, selling an estimated $988K and leaving 2,270 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.
Group One Trading first reported a position in ALNY in Q2 2013 and has held it in 30 quarters since. The position peaked at $9.07M in Q2 2022. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Group One Trading held 2,270 shares of Alnylam Pharmaceuticals worth $683K as of Q2 2026.
- Group One Trading sold 3,275 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $988K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3218 holding.
- Group One Trading first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
- Group One Trading's Alnylam Pharmaceuticals position peaked at $9.07M in Q2 2022.
- 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.